A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explore

Trial Details

NCT ID
NCT05283720
Phase
PHASE2
Sponsor
Genmab
Status
RECRUITING
Cancer Type
Hairy Cell Leukemia Leukemia
Interventions
  • Epcoritamab
  • Lenalidomide
  • Ibrutinib
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin Hydrochloride [HCl]
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Newark, Delaware, United States|39.68372,-75.74966
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Diagnosis of:
  • \-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) wit…
  • DLBCL, not otherwise specified (NOS).
  • High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymph…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hairy Cell Leukemia Leukemia Trials on Trialify →